These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 11706702)
21. Altered cleavage site preference of a proteolytic antibody light chain induced by denaturation. Sun M; Paul S FEBS Lett; 1997 May; 407(3):289-90. PubMed ID: 9175870 [TBL] [Abstract][Full Text] [Related]
22. Targeted destruction of the HIV-1 coat protein gp41 by a catalytic antibody light chain. Hifumi E; Mitsuda Y; Ohara K; Uda T J Immunol Methods; 2002 Nov; 269(1-2):283-98. PubMed ID: 12379368 [TBL] [Abstract][Full Text] [Related]
23. A preliminary study for isolation of catalytic antibodies by histidine ligand affinity chromatography as an alternative to conventional protein A/G methods. Nedonchelle E; Pitiot O; Vijayalakshmi MA Appl Biochem Biotechnol; 2000; 83(1-3):287-94; discussion 294-5, 297-313. PubMed ID: 10826967 [TBL] [Abstract][Full Text] [Related]
24. Systemic lupus erythematosus and spontaneously arising anticoagulants. Jacobs P; Bracher M; Meyers OL S Afr Med J; 1975 Oct; 49(45):1881-2. PubMed ID: 1188558 [TBL] [Abstract][Full Text] [Related]
25. Prothrombin-antibody coexistent with lupus anticoagulant (LA): clinical study and immunochemical characterization. Baudo F; Redaelli R; Pezzetti L; Caimi TM; Busnach G; Perrino L; deCataldo F Thromb Res; 1990 Jan; 57(2):279-87. PubMed ID: 2107592 [TBL] [Abstract][Full Text] [Related]
26. Nucleotide-hydrolyzing antibodies from the sera of autoimmune-prone MRL-lpr/lpr mice. Andryushkova AA; Kuznetsova IA; Orlovskaya IA; Buneva VN; Nevinsky GA Int Immunol; 2009 Aug; 21(8):935-45. PubMed ID: 19556305 [TBL] [Abstract][Full Text] [Related]
27. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies. Ulrich HD; Schultz PG J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442 [TBL] [Abstract][Full Text] [Related]
28. Prothrombin binds to the surface of apoptotic, but not viable, cells and serves as a target of lupus anticoagulant autoantibodies. D'Agnillo P; Levine JS; Subang R; Rauch J J Immunol; 2003 Mar; 170(6):3408-22. PubMed ID: 12626602 [TBL] [Abstract][Full Text] [Related]
31. A new catalytic site functioning in antigen cleavage by H34 catalytic antibody light chain. Hifumi E; Nonaka T; Taguchi H; Uda T Sci Rep; 2022 Nov; 12(1):19185. PubMed ID: 36357546 [TBL] [Abstract][Full Text] [Related]
32. Systemic lupus erythematosus: molecular cloning and analysis of recombinant monoclonal kappa light chain NGTA2-Me-pro-ChTr possessing two different activities-trypsin-like and metalloprotease. Timofeeva AM; Ivanisenko NV; Buneva VN; Nevinsky GA Int Immunol; 2015 Dec; 27(12):633-45. PubMed ID: 26174315 [TBL] [Abstract][Full Text] [Related]
33. [Features of tRNA hydrolysis by autoantibodies from blood serum of patients with certain autoimmune and virus diseases]. Vlasov AV; Helm M; Naumov VA; Breusov AA; Buneva VN; Florentz C; Giege R; Nevinskiĭ GA Mol Biol (Mosk); 1999; 33(5):866-72. PubMed ID: 10579192 [No Abstract] [Full Text] [Related]
34. Catalytic antibodies in clinical and experimental pathology: human and mouse models. Ponomarenko NA; Durova OM; Vorobiev II; Aleksandrova ES; Telegin GB; Chamborant OG; Sidorik LL; Suchkov SV; Alekberova ZS; Gnuchev NV; Gabibov AG J Immunol Methods; 2002 Nov; 269(1-2):197-211. PubMed ID: 12379362 [TBL] [Abstract][Full Text] [Related]
35. A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/β₂ glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies. Hirakawa E; Saito K; Hirata S; Atsumi T; Koike T; Tanaka Y Mod Rheumatol; 2012 Sep; 22(5):769-73. PubMed ID: 22124547 [TBL] [Abstract][Full Text] [Related]
36. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. Bertolaccini ML; Atsumi T; Khamashta MA; Amengual O; Hughes GR J Rheumatol; 1998 Jun; 25(6):1104-8. PubMed ID: 9632071 [TBL] [Abstract][Full Text] [Related]
37. Design of a serine protease-like catalytic triad on an antibody light chain displayed on the yeast cell surface. Okochi N; Kato-Murai M; Kadonosono T; Ueda M Appl Microbiol Biotechnol; 2007 Dec; 77(3):597-603. PubMed ID: 17899065 [TBL] [Abstract][Full Text] [Related]
38. Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies. Kim SH; Schindler DG; Lindner AB; Tawfik DS; Eshhar Z Mol Immunol; 1997; 34(12-13):891-906. PubMed ID: 9464525 [TBL] [Abstract][Full Text] [Related]
39. Systemic lupus erythematosus: molecular cloning and analysis of recombinant DNase monoclonal κ light chain NGK-1. Kostrikina IA; Odintsova ES; Buneva VN; Nevinsky GA Int Immunol; 2014 Aug; 26(8):439-50. PubMed ID: 24919596 [TBL] [Abstract][Full Text] [Related]
40. Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain. Sun M; Gao QS; Kirnarskiy L; Rees A; Paul S J Mol Biol; 1997 Aug; 271(3):374-85. PubMed ID: 9268666 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]